---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-164330"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:17:44.795239+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio completes spin-off of First Tracks Biotherapeutics (TRAX); distribution effective April 20, 2026

## Summary
- Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.
- First Tracks started trading on Nasdaq under ticker TRAX on April 20, 2026.
- AnaptysBio retains royalty management for dostarlimab (Jemperli) and imsidolimab from Vanda.
- First Tracks receives $100M cash, up to $35M in Vanda milestones, and clinical assets rosnilimab, ANB033, ANB101.
- Separation and Distribution Agreement allocates assets/liabilities between royalty management and biotech businesses.

## SEC filing metadata
- accession: 0001193125-26-164330
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/0001193125-26-164330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/d120122d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-164330
- JSON: https://secwatch.observer/filing/0001193125-26-164330.json
- Plain text: https://secwatch.observer/filing/0001193125-26-164330.txt

## Source-grounded claims
- claim_id: 08637338127a5c4c1dbd16f992c88b4733ff84be
  claim: ANAPTYSBIO, INC completed a disposition involving First Tracks Biotherapeutics, Inc. (closed 2026-04-20).
  evidence_excerpt: completed the previously announced separation (the "Spin-Off") of First Tracks Biotherapeutics, Inc. ("First Tracks Biotherapeutics") from the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/0001193125-26-164330-index.htm
- claim_id: a2153f97566840838e5f6f6ce279a91de4d69d07
  claim: ANAPTYSBIO, INC entered into Separation and Distribution Agreement with First Tracks Biotherapeutics valued at $100.0 million.
  evidence_excerpt: the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/0001193125-26-164330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.